The offshoot starts life with seed funding and an RNA-based program targeting a rare genetic disease that causes strokes.

The red-blood-cell-encapsulated L-asparaginase improved overall survival and other outcomes in metastatic pancreatic cancer patients.

After getting off a $102 million series A, Gritstone Oncology has followed up with an impressive $92.7 million second round.

Wednesday's shot of your news of note.

The anticipated haul will fund late-phase trials of NuCana’s reformulated cancer candidates, including a version of Eli Lilly’s Gemzar.

Destiny's IPO gives it £15.3 million to assess lead candidate XF-73 in the prevention of postsurgical staphylococcal infections in a phase 2b trial.

OrbiMed has launched its third Asia-focused biopharma and healthcare fund with more than half a billion dollars’ worth of private equity.

Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.

Venture Capital